Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Abiprubart · KPL-404

Monoclonal antibody · developed by Kiniksa Pharmaceuticals

Phase 2 Most advanced trial (none active)
KNSA Developer
2 Registered trials

What is Abiprubart?

Abiprubart (KPL-404) is a humanized monoclonal antibody. It is studied in rheumatoid arthritis and Sjögren's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KPL-404
Drug type
Monoclonal antibody
Therapy area
Immunology
Developer
Kiniksa Pharmaceuticals, Ltd. (KNSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
TIN30KQI3W

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06531395 Phase 2 Sjögrens Disease Terminated KNSA
NCT05198310 Phase 2 Arthritis, Rheumatoid Completed KNSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Arthritis, RheumatoidSjögrens Disease

More from Kiniksa Pharmaceuticals

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.

Follow KNSA, the company behind Abiprubart

See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KNSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.